Arena Pharmaceutical Licenses Exclusive Worldwide Rights of Ralinepag (APD811) to United Therapeutics for $1.2B

 Arena Pharmaceutical Licenses Exclusive Worldwide Rights of Ralinepag (APD811) to United Therapeutics for $1.2B

Arena Pharmaceutical Licenses Exclusive Worldwide Rights of Ralinepag (APD811) to United Therapeutics for $1.2B

Shots:

  • Arena to get $1.2B as total deal value, including $800M upfront plus $400M milestones and royalties on net sales of the product. United to get exclusive worldwide rights to develop & commercialize Ralinepag
  • The focus of the agreement is to develop Ralinepag for long-term success with an expectation to treat 10,000 patients annually from the 2020s to 2030s
  • Ralinepag PO is a qd IP receptor agonist evaluated currently in P-III, indicated for the treatment of pulmonary arterial hypertension (PAH)

Click here to read full press release/ article | Ref: United Therapeutics | Image: PR Newswire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post